Precigen vs Zenas BioPharma
Zenas BioPharma reported revenue of $10 million in fiscal 2025, about the same as Precigen's $10 million in fiscal 2025. Precigen's revenue grew 146.7% in its latest year, and Zenas BioPharma's grew 100.0%. Precigen had an operating margin of -1141.1%, against -3830.6% at Zenas BioPharma. Free cash flow was −$90 million at Precigen and −$172 million at Zenas BioPharma.
Side by side
| Precigen | Zenas BioPharma | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $10M | $10M |
| Revenue growth | 146.7% | 100.0% |
| Revenue growth a year, last 5 years | −21.2% | — |
| Gross margin | — | — |
| Operating margin | −1,141.1% | −3,830.6% |
| Net margin | −2,588.2% | −3,777.4% |
| Free cash flow | −$90M | −$172M |
| Free cash flow margin | −927.6% | −1,723.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 16.9% | 238.9% |
| Last close | $4.54 | $28.01 |
| P/E at the last close | 45.4× | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 2 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
PrecigenZenas BioPharma
Operating margin
Percent of revenue
PrecigenZenas BioPharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
PrecigenZenas BioPharma
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Precigen and Zenas BioPharma pages.